XML 24 R13.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
EQUITY BASED COMPENSATION
 3 Months Ended
Mar. 31, 2024
Share-Based Payment Arrangement [Abstract]  
EQUITY BASED COMPENSATION EQUITY BASED COMPENSATION
In February 2021, Greenidge adopted an equity incentive plan and reserved 383,111 shares of Class A common stock for issuance under the plan (the “2021 Equity Plan”), applicable to employees and non-employee directors. In April 2023, the stockholders approved an amendment and restatement of the Company's 2021 Equity Plan to increase the maximum aggregate number of shares of Class A common stock that may be issued for all purposes under the Plan by 500,000 shares of Class A common stock from 383,111 to 883,111 shares of Class A common stock and to remove the counting of shares of Class A common stock granted in connection with awards other than stock options and stock appreciation rights against the total number of shares available under the Plan as two shares of Class A common stock for every one share of Class A common stock granted in connection with such award. For the three months ended March 31, 2024, no additional shares had been granted under the 2021 Equity Plan. In October 2022, the Company registered 307,684 shares of Class A common stock, outside the 2021 Equity Plan, that were reserved for issuance upon the vesting and exercise of non-qualified stock options inducement grants.
RSAs and RSUs
Restricted stock awards ("RSA") are generally granted with an eligible vesting range from upon grant to over a three-year period. Restricted stock unit ("RSU") awards are generally eligible to vest over a three-year period.
The Company’s unvested RSA and RSU award activity for the three months ended March 31, 2024 is summarized below:
RSAs & RSUsWeighted Average
Grant Date
Fair Value
Unvested at December 31, 20239,116$62.99 
Granted247,469$4.32 
Vested(124,495)$9.14 
Unvested at March 31, 2024132,090$3.79 
The value of RSA and RSU grants are measured based on their fair market value on the date of grant and amortized over their requisite service periods. The fair market value of the awards granted totaled $1.1 million for the three months ended March 31, 2024. There were no grants awarded during the three months ended March 31, 2023. At March 31, 2024, there was approximately $0.4 million of total unrecognized compensation cost related to unvested restricted stock rights, which is expected to be recognized over a remaining weighted-average vesting period of approximately 1.7 years.
Common Stock Options
The Company’s common stock options activity for the three months ended March 31, 2024 is summarized below:
Options Weighted Average
Exercise Price
Per Share		Weighted Average
Remaining
Contractual Life
(in years)		Aggregate
Intrinsic
Value
Outstanding at December 31, 2023458,982 $16.59 
Forfeited(266)$62.50  
Expired(535)$64.83 
Outstanding at March 31, 2024458,181$16.51 8.59$— 
Exercisable as of March 31, 2024152,193$28.25 7.99$— 
The value of common stock option grants is measured based on their fair market value on the date of grant and amortized over their requisite service periods. At March 31, 2024, there was approximately $2.0 million of total unrecognized compensation cost related to unvested common stock options, which is expected to be recognized over a remaining weighted-average vesting period of approximately 1.9 years.
Stock-Based Compensation
The Company recognized stock-based compensation expense of $1.1 million and $0.5 million during the three months ended March 31, 2024 and 2023, respectively. Stock-based compensation expense is included in selling, general and administrative expenses in the accompanying unaudited condensed consolidated statements of operations and comprehensive loss.